Patents Assigned to Cytomx Therapeutics, Inc.
-
Publication number: 20240124546Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.Type: ApplicationFiled: May 25, 2023Publication date: April 18, 2024Applicant: CytomX Therapeutics, Inc.Inventors: Sayantan MITRA, Nicole G. LAPUYADE, Hikmat Haizar ASSI, Madan M. PAIDHUNGAT, Dylan L. DANIEL, Erwan LE SCOLAN, Walter A. BOGDANOFF, Na CAI, Hsin WANG, Alexey Yevgenyevich BEREZHNOY
-
Patent number: 11952427Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: March 15, 2022Date of Patent: April 9, 2024Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
-
Publication number: 20240084010Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: September 22, 2023Publication date: March 14, 2024Applicant: CytomX Therapeutics, Inc.Inventors: Bryan Allen IRVING, Sherry Lynn LA PORTE, Jason Gary SAGERT, Daniel Robert HOSTETTER, Olivia Jennifer RAZO, Clayton William WHITE, Jennifer Hope RICHARDSON
-
Patent number: 11890354Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: June 4, 2020Date of Patent: February 6, 2024Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 11884746Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: April 26, 2021Date of Patent: January 30, 2024Assignee: CytomX Therapeutics, Inc.Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva
-
Patent number: 11867695Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.Type: GrantFiled: April 30, 2021Date of Patent: January 9, 2024Assignee: CytomX Therapeutics, Inc.Inventors: Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 11859010Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.Type: GrantFiled: September 7, 2022Date of Patent: January 2, 2024Assignee: CytomX Therapeutics, Inc.Inventors: Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
-
Patent number: 11814410Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: November 2, 2018Date of Patent: November 14, 2023Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel R. Hostetter, Olga Vasiljeva, Jeanne Grace Flandez
-
Patent number: 11802158Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: April 24, 2020Date of Patent: October 31, 2023Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
-
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
Publication number: 20230212283Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: December 7, 2022Publication date: July 6, 2023Applicant: Cytomx Therapeutics, Inc.Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST -
Publication number: 20230192798Abstract: Provided herein are methods of treating a subject by administering a combination of an activatable cytokine construct (ACC) and a PD-1/PD-L1 pathway inhibitor in which the ACC includes: a first monomer construct including an optional first peptide mask (PM1), an optional third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and a second monomer construct including an optional second peptide mask (PM2), an optional forth cleavable moiety (CM4), a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), wherein the CM2 is positioned between the CP2 and the DD2; wherein the DD1 and the DD2 bind to each other thereby forming a dimer of the first monomer construct and the second monomer construct; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control lType: ApplicationFiled: October 6, 2022Publication date: June 22, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Alexey Yevgenyevich Berezhnoy, Nicole G. Lapuyade, Na Cai, Michael B. Winter, Kenneth Wong, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan
-
Publication number: 20230183382Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.Type: ApplicationFiled: October 14, 2022Publication date: June 15, 2023Applicants: CytomX Therapeutics, Inc., Amgen, Inc.Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
-
Publication number: 20230183308Abstract: A proprotein containing a functional protein coupled to a peptide mask that inhibits binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask.Type: ApplicationFiled: December 19, 2022Publication date: June 15, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Publication number: 20230174995Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.Type: ApplicationFiled: October 14, 2022Publication date: June 8, 2023Applicants: CytomX Therapeutics, Inc., Amgen, Inc.Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
-
Patent number: 11667687Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.Type: GrantFiled: March 16, 2022Date of Patent: June 6, 2023Assignee: CytomX Therapeutics, Inc.Inventors: Sayantan Mitra, Nicole G. Lapuyade, Hikmat Haizar Assi, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan, Walter A. Bogdanoff, Na Cai, Hsin Wang, Alexey Yevgenyevich Berezhnoy
-
Publication number: 20230057263Abstract: Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3?). Also provided herein are anti-idiotypic antibodies that bind specifically to any of the antigen-binding domains described herein.Type: ApplicationFiled: January 6, 2021Publication date: February 23, 2023Applicant: CYTOMX THERAPEUTICS, INC.Inventors: Christopher KEMBALL, Pia CHALLITA-EID, Rene HUBERT
-
Publication number: 20230050083Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.Type: ApplicationFiled: September 7, 2022Publication date: February 16, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Leila Marie BOUSTANY, Sherry L. LA PORTE, Bryan A. IRVING, Jeanne Grace FLANDEZ
-
Publication number: 20230035290Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: ApplicationFiled: March 21, 2022Publication date: February 2, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
Publication number: 20230021301Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 28, 2021Publication date: January 19, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST -
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
Patent number: 11548943Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: June 28, 2021Date of Patent: January 10, 2023Assignee: CytomX Therapeutics, Inc.Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West